A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.
USA115th CongressS-1681| Senate
| Updated: 7/31/2017
Bernard Sanders
Independent Senator
Vermont
Health, Education, Labor, and Pensions Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Drug safety, medical device, and laboratory regulationHealth programs administration and fundingHealth technology, devices, suppliesInflation and pricesIntellectual propertyMedical researchResearch and development
A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.
USA115th CongressS-1681| Senate
| Updated: 7/31/2017
This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Bernard Sanders
Independent Senator
Vermont
Health, Education, Labor, and Pensions Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Drug safety, medical device, and laboratory regulationHealth programs administration and fundingHealth technology, devices, suppliesInflation and pricesIntellectual propertyMedical researchResearch and development